CYP3A4/5 (F386) Peptide 
Datasheet
COA
MSDS
SHIP
Product Name :
CYP3A4/5 (F386) Peptide Applications :
Blocking Background :
Cytochrome P450 3A (CYP3A) genes encode monooxygenases—enzymes which catalyze drug metabolism and the synthesis of cholesterol, steroids and other lipids. CYP3A, the most abundant p450 enzyme in human liver, is responsible for the metabolism of more than 50% of all clinical drugs. CYP3A family members localize in organs that associate with drug disposition, including the liver, gastrointestinal tract and kidney. The CYP3A cluster maps to gene locus 7q21.3-q22.1 and consists of four genes (CYP3A4, CYP3A5, CYP3A7 andCYP3A43) and two pseudogenes (CYP3A5P1 and CYP3A5P2). CYP3A4 is abundant in the endoplasmic reticulum of liver cells and upper intestinal enterocytes. CYP3A4 expression is inducible by glucocorticoids pharmacological agents. Alternative Name :
Cytochrome P450 3A4; 1,8-cineole 2-exo-monooxygenase; Albendazole monooxygenase; Albendazole sulfoxidase; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; Taurochenodeoxycholate 6-alpha-hydroxylase; CYP3A4; CYP3A3; Cytochrome P450 3A5; CYPIIIA5; Cytochrome P450 HLp2; Cytochrome P450-PCN3; CYP3A5 Swiss-Prot :
P08684/P20815 Product :
1 mg/ml in DI water. Purification&Purity :
Synthetic peptide CYP3A4/5 (F386). (Note: the amino acid sequence is proprietary). The purity is > 98%. Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
This peptide can be used with studies using BS2197 CYP3A4/5 (F386) pAb.
CYP3A4/5 (F386) Peptide Applications :
Blocking Background :
Cytochrome P450 3A (CYP3A) genes encode monooxygenases—enzymes which catalyze drug metabolism and the synthesis of cholesterol, steroids and other lipids. CYP3A, the most abundant p450 enzyme in human liver, is responsible for the metabolism of more than 50% of all clinical drugs. CYP3A family members localize in organs that associate with drug disposition, including the liver, gastrointestinal tract and kidney. The CYP3A cluster maps to gene locus 7q21.3-q22.1 and consists of four genes (CYP3A4, CYP3A5, CYP3A7 andCYP3A43) and two pseudogenes (CYP3A5P1 and CYP3A5P2). CYP3A4 is abundant in the endoplasmic reticulum of liver cells and upper intestinal enterocytes. CYP3A4 expression is inducible by glucocorticoids pharmacological agents. Alternative Name :
Cytochrome P450 3A4; 1,8-cineole 2-exo-monooxygenase; Albendazole monooxygenase; Albendazole sulfoxidase; CYPIIIA3; CYPIIIA4; Cytochrome P450 3A3; Cytochrome P450 HLp; Cytochrome P450 NF-25; Cytochrome P450-PCN1; Nifedipine oxidase; Quinine 3-monooxygenase; Taurochenodeoxycholate 6-alpha-hydroxylase; CYP3A4; CYP3A3; Cytochrome P450 3A5; CYPIIIA5; Cytochrome P450 HLp2; Cytochrome P450-PCN3; CYP3A5 Swiss-Prot :
P08684/P20815 Product :
1 mg/ml in DI water. Purification&Purity :
Synthetic peptide CYP3A4/5 (F386). (Note: the amino acid sequence is proprietary). The purity is > 98%. Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
This peptide can be used with studies using BS2197 CYP3A4/5 (F386) pAb.
Blocking peptide available as BS2197PP